Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
Federal PolicyNovember 19, 2026

Senate Judiciary Members Admit Drug Pricing Bills Remain Stalled

At a Senate Judiciary Committee hearing, lawmakers including Sen. John Kennedy (R-La.) acknowledged that Congress has failed to advance drug pricing reform despite Republican control, with Kennedy calling the inaction "zero, zilch, nada." Chairman Chuck Grassley (R-Iowa) noted the committee advanced six bipartisan bills last year targeting drugmaker and PBM practices, but only one, the Affordable Prescriptions for Patients Act, reached the Senate floor; Grassley cited a crowded calendar and industry pushback as likely factors. Witnesses, including Patients for Affordable Drugs Now CEO Merith Basey and Cost Plus Drug Company CEO Alex Oshmyansky, testified that the bills should pass as a package to address patent abuses like product hopping and patent thickets, and that PBM consolidation among CVS Caremark, Express Scripts and OptumRx drives high costs and limits competition.

Why it mattersState Medicaid agencies and pharmacy stakeholders tracking PBM reform may face continued uncertainty over federal action on drug pricing and PBM transparency requirements that could affect Medicaid pharmacy benefit administration.

Pharmacy

Read the full article at healthcaredive.com →
Share this briefing

You might also like

← All stories

Get the daily briefing.